MBS301
/ Beijing Mabworks Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 23, 2023
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Aug 2023 ➔ Dec 2024
Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • HER-2
November 14, 2022
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Aug 2022 ➔ Aug 2023
Trial completion date • Trial primary completion date • Oncology • Solid Tumor • HER-2
March 03, 2022
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Dec 2020 ➔ Dec 2022 | Trial primary completion date: May 2020 ➔ Aug 2022
Trial completion date • Trial primary completion date • Oncology • Solid Tumor • HER-2
1 to 3
Of
3
Go to page
1